openPR Logo
Press release

Cancer Immunotherapy Has Emerged As Next Growth Frontier With US$ 200 Billion In Market Opportunity

04-07-2020 01:30 PM CET | Health & Medicine

Press release from: Kuick Resarch

"Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

o Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion
o Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials
o Commercially Available Cancer Immunotherapies: > 120
o Cancer Vaccines Market Opportunity: > US$ 20 Billion
o Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion
o Marketed Cancer Monoclonal Antibodies': > 70 mAbs
o Sales, Market Opportunity, Dosage & Price Data: 300 Graphs/Charts
o Clinical Trials Insight By Phase, Company, Patient Segment, Drug Class

Download Report:,-dosage,-price-and-clinical-trials-insight-2026.php

The research report "Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" discusses the implications that the recent scientific research and development has brought in context to the ongoing trends and current market size of the cancer immunotherapy at global and regional level. Additionally, the report depicts the nature of the therapies and the structures that are followed by the cancer immunotherapy approach with detailed profiles of the pharmaceutical companies that are the keynote representer of immunotherapy products in the market.

Table of Contents

1. Immunotherapy for Cancer

1.1 Introduction to Cancer Immunotherapy
1.2 Advancement of Cancer Immunotherapy

2. Types of Cancer Immunotherapy

2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies

2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors

3. Dynamics of Global Cancer Immunotherapy Landscape

3.1 Favorable Developmental & Commercialization Parameters
3.2 Issues to be Resolved in Expansion of Immunotherapy Horizon

4. Cancer Vaccines: Transforming The Immunotherapy Landscape

4.1 Prologue of Cancer Vaccines
4.2 Cancer Vaccines in Immunotherapy
4.3 Commercialization of Cancer Vaccines

5. Monoclonal Antibodies: New Era of Immunotherapy

5.1 Rudiments of Monoclonal Antibodies
5.2 Advents of Monoclonal Antibodies
5.3 Commercial Aspects of Monoclonal Antibodies

6. Trails of T-Cell Therapies

6.1 Adoptive Cell Transfer Technology
6.2 Strategies of Adoptive Cell Transfer
6.3 Commercial Aspects of Adoptive Cell Therapy

7. Application of Immune Checkpoint Inhibitors in Immunotherapy

7.1 Prelude to Immune Checkpoint Inhibitors
7.2 Implications of Immunecheck Point Inhibitors
7.3 Commercial Aspects of Immune Checkpoint Inhibitors

8. Role of Immunomodulators in Cancer Immunotherapy

8.1 Perspective of Immunomodulators
8.2 Clinical Aspects of Immunomodulators
8.3 Commercial Aspects of Immunomodulators

9. Development of Oncolytic Viral Immunotherapy

9.1 Concept to Oncolytic Viruses
9.2 Potential Approaches of Oncolytic Viruses
9.3 Commercial Aspects of Oncolytic Viruses

10. Cytokines & Cancer Immunotherapy

10.1 Fundamentals of Cytokines
10.2 Classification of Cytokines
10.3 Commercial Aspects of Cytokines

11. Interferons in Immunotherapy

11.1 Potentials of Interferons
11.2 Classification of Interferons
11.3 Clinical Applications of Interferons

12. Interleukins in Immunotherapy

12.1 Potentials of Interleukins
12.2 Clinical Applications of Interleukins

13. GM-CSF in Immunotherapy

13.1 Potentials of GM-CSF
13.2 Clinical Applications of GM-CSF

14. Market Aspects of Cancer Immunotherapy

14.1 Current Market Trends
14.2 Economic Aspects of Cancer Immunotherapy
14.3 Cancer Immunotherapy Cost by Product

15. Cancer Immunotherapy Pipeline Overview

15.1 By Drug Class
15.2 By Phase
15.3 By Company
15.4 By Target
15.5 By Patient Segment

16. Cancer Immune Check Point Inhibitors - Availability, Price, Dosage & Sales Analysis

16.1 Keytruda (Pembrolizumab)
16.2 Yervoy (Ipilimumab)
16.3 Opdivo (Nivolumab)
16.4 Tecentriq (Atizolizumab)
16.5 Bavencio (Avelumab)
16.6 Imfinzi (Darlumuvab)
16.7 Libtayo (Cemiplimab)

17. Cancer Monclonal Antibody Market - Availability, Price, Dosage & Sales Analysis

17.1 Herceptin (Trastuzumab)
17.2 Avastin (Bevacizumab)
17.3 MabThera/Rituxan (Rituximab)
17.4 Erbitux (Cetuximab)
17.5 Vectibix (Panitumab)
17.6 Arzerra (Ofatumumab)
17.7 Gazyva (Obinutuzumab)
17.8 Perjeta (Pertuzumab)

18. Bispecific Antibody Market - Availability, Price, Dosage & Sales Analysis

18.1 Blincyto (Blinatumomab)

19. Cancer Vaccine Market - Availability, Price, Dosage & Sales Analysis

19.1 Gardasil & Gardasil 9
19.2 Cervarix
19.3 Provenge (Sipuleucel - T)
19.4 Vaxira (Racotumomab)
19.5 CreaVax-RCC

20. Cancer Cytokines Drugs Market - Availability, Price, Dosage & Sales Analysis

20.1 Proleukin (Aldeslukin)
20.2 Intron A (Interferon Alpha-2b)
20.3 PegIntron (PegInterferon alpha-2b)
20.4 Sylatron (Peginterferon Alpha-2b)
20.5 Betaseron (Interferon Beta-1b)
20.6 Actimmune (Interferon Gamma-1b)
20.7 Ontak (Denileukin Diftitox)

21. Oncolytic Virus Market - Availability, Dosage, & Price Analysis

21.1 Imlygic
22. CAR-T Cell Therapy - Availability, Dosage, Price & Sales Analysis
22.1 Kymriah
22.2 Yescarta

23. Marketed Cancer Cell Therapies Drugs

23.1 T-Lymphocyte Cell Therapy(Immuncell-LC)
23.2 Zalmoxis
23.4 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

24. Marketed Cancer Cytokines Drugs

24.1 Aldesleukin (Proleukin)
24.2 Denileukin Diftitox (ONTAK)
24.3 Interferon Alpha (Multiferon)
24.4 Interferon Alpha-2a (Roferon-A)
24.5 Interferon Alpha-2a (Veldona)
24.6 Interferon Alpha-2a Biosimilar(Inferon(TM)/Inmutag(TM))
24.7 Interferon Alpha-2b(Intron A)
24.8 Interferon Alpha-2b Biosimilar(Bioferon(TM))
24.9 Interferon Alpha-2b Biosimilar (Intalfa)
24.10 Interferon Alpha-2b Biosimilar
24.11 Interferon Alpha-2b Biosimilar (ReliFeron)
24.12 Interferon-Alpha-n3 (Alferon N)
24.13 Interferon-Beta-1b (Feron)
24.14 Interferon-Gamma (Ogamma)
24.15 Interleukin-2 Biosimilar (Ilcass)
24.16 Teceleukin (Imunace(TM))

25. Marketed Cancer Vaccines

25.1 Bladder Cancer Vaccine (PACIS)
25.2 Bladder Cancer Vaccine
25.3 BV NSCLC 001
25.4 Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
25.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil/Silgard)
25.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix)
25.7 Immuvac / Cadi 05
25.8 Immucyst / TheraCys
25.9 Melanoma Vaccine (MVax)
25.10 Melanoma Vaccine (Melacine)
25.11 Racotumomab (Vaxira)
25.12 Reniale
25.13 Sipuleucel-T (Provenge)
25.14 Tertomotide (LucaVax)
25.15 Vitespen (Oncophage)

26. Marketed Cancer Monoclonal Antibodies

26.1 Bevacizumab
26.2 Trastuzumab Emtansine
26.3 Trastuzumab Subcutaneous
26.4 Brentuximab Vedotin
26.5 Catumaxomab
26.6 Ipilimumab
26.7 Nivolumab
26.8 Pembrolizumab
26.9 Pertuzumab
26.10 Rituximab
26.11 Trastuzumab
26.12 Gemtuzumab Ozogamicin
26.13 Others

27. Global Cancer Immunotherapy Market Future Prospects

28. Competitive Landscape

28.1 Abbvie
28.2 Advaxis
28.3 Altor BioScience
28.4 Amgen
28.5 Biogen Idec
28.6 Biogenomics
28.7 Celldex Therapeutics
28.8 Dendreon Corporation
28.9 Eli Lilly
28.10 Expression Genetics
28.11 Galena Biopharma
28.12 Genmab
28.13 Gilead Sciences
28.14 GlaxoSmithKline
28.15 ImmunoCellular Therapeutics
28.16 ImmunoGen
28.17 Inovio Pharmaceuticals
28.18 IRX Therapeutics
28.19 Merck
28.20 NeoStem Oncology
28.21 NewLink Genetics
28.22 Northwest Biotherapeutics
28.23 Novartis
28.24 Peregrine Pharmaceuticals
28.25 Pfizer
28.26 Philogen
28.27 Regulon
28.28 Roche
28.29 Seattle Genetics
28.30 ZymoGenetics

Neeraj Chawla

104, Ansal Building
Delhi, India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Immunotherapy Has Emerged As Next Growth Frontier With US$ 200 Billion In Market Opportunity here

News-ID: 2001904 • Views: 764

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases

More Releases for Cancer

Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and
Natural Cancer Treatment
Cancer is going to be the number one killer in the world beginning from the year 2010! Facts of Cancer Cancer is a group of over 100 diseases that cause the cells in your body to grow to an uncontrollable level, as their normal growth regulating mechanism experiences an imbalance due to numerous external and internal factors. Many of the reasons for this scenario to occur are still unknown to medical science. However,